Prostate cancer progression increases the mesenchymal markers N-cadherin and vimentin; N-cadherin promotes EMT via activation of the ErbB signaling pathway and enhances the migratory and invasive potential of cancer cells [24]. Here, CDH2 is linked to prostate carcinoma.